MOXATAG® Supports Health Education on FamilyDoctor.org

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), the maker of the first and only FDA-approved once-daily amoxicillin, MOXATAG (extended-release amoxicillin) Tablets, 775 mg, announced today that it is supporting educational content on consumer health Web site FamilyDoctor.org. FamilyDoctor.org was recently named one of “Five Great Health Sites” on a Newsweek.com blog and one of the “‘Top Ten’ Most Useful Web Sites” by the Medical Library Association.

MOXATAG is indicated for the treatment of tonsillitis and pharyngitis secondary to Streptococcus pyogenes, more commonly known as strep throat, in patients 12 years and older. MiddleBrook offers a patient co-pay assistance program for MOXATAG, which allows most commercially-insured patients to pay no more than $20 for a MOXATAG prescription. The MOXATAG $20 maximum co-pay voucher can be downloaded at MOXATAG.com and via FamilyDoctor.org.

“We are proud to support FamilyDoctor.org, the only consumer health web site brought to you by a professional medical organization, the American Academy of Family Physicians,” said Frank Koos, senior vice president of sales, marketing and business development for MiddleBrook Pharmaceuticals. “We are committed to increasing awareness about appropriate antibiotic usage, and we commend FamilyDoctor.org for featuring physician-reviewed information on important health topics such as strep throat.”

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on developing and commercializing anti-infective products that fulfill unmet medical needs. MiddleBrook’s proprietary delivery technology—PULSYS—enables the pulsatile delivery, or delivery in rapid bursts, of certain drugs. MiddleBrook’s near-term corporate strategy includes improving dosing regimens and/or reducing frequency of dosing to enhance patient dosing convenience and compliance for antibiotics that have been used and trusted by physicians and patients for decades. MiddleBrook currently markets KEFLEX (cephalexin, USP), the immediate-release brand of cephalexin, and MOXATAG–the first and only FDA-approved once-daily amoxicillin. For more information about MiddleBrook, please visit www.middlebrookpharma.com.

MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook Pharmaceuticals, Inc. and MOXATAG are our trademarks and have been registered in the U.S. Patent and Trademark Office or are the subject of pending U.S. trademarks applications. Each of the other trademarks, tradenames, or service marks appearing in this document belongs to the respective holder, as used herein, except as otherwise indicated by the context.

About MOXATAG:

MOXATAG (amoxicillin extended-release) Tablets, 775mg, is a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release component and two delayed-release components. The three components of MOXATAG are combined in a specific ratio to prolong the release of amoxicillin compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis. For more information about MOXATAG, please visit MOXATAG.com.

Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
Historical Stock Chart
From Apr 2024 to May 2024